Related Insights
CPI's Steepest Drop in Six Years: What Lower Inflation Means for Chemical Regulatory Cost Assessments
June's 0.4% decline in the Consumer Price Index marked the largest monthly drop in more than six years, creating new considerations for chemical regulatory cost assessments. Procurement and compliance teams should understand how inflation trends influence regulatory analysis and future compliance costs.
REACH SVHC July Update: Regulatory Intelligence for Chemical Procurement Compliance
The anticipated July to August 2026 REACH SVHC candidate list update could introduce new notification obligations for chemical manufacturers, importers and downstream users. Procurement and compliance teams should prepare now to respond quickly when the revised candidate list is published.
Qatar Chemical Watch: Diplomatic Ambiguity & Energy Resilience
Qatar sits at the crossroads of geopolitical uncertainty and commercial strain as US‑Iran talks stall and LNG disruptions persist. Chemical buyers now question whether QatarEnergy can honour investment plans and restore export flows while QAFCO navigates force majeure timelines. The outcome will reshape ammonia, urea, and fertilizer pricing across Asia.
48 Force Majeures Remain: The Real Chemical Supply Recovery Signal
When shipping volumes plateau, the true pulse of the chemical market lies in the number of force majeure declarations. 48 active notices this month paint a picture of gradual recovery and reveal where supply disruptions still loom. In the ICIS chemical market, fewer force majeure claims mean a smoother flow of raw materials and finished goods.
EU REACH SVHC July 2026 Update: Expected Substances and Procurement Implications
The upcoming ECHA SVHC update under EU REACH is expected between July and August 2026, with potential additions affecting flame retardants, phthalates and organotin compounds. Chemical buyers should prepare supplier declarations and compliance updates before the July 31 deadline window closes.
Pharmaceutical Chemical Procurement Intelligence: June 24, 2026 Situation Report
Pharmaceutical procurement teams face an unusually complex H2 2026 environment shaped by GLP-1 manufacturing demand, excipient compliance changes, freight cost shifts, regulatory deadlines, and elevated drug shortage risk across critical therapeutic categories.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.